New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
09:13 EDTABTAbbott sees accelerating sales growth in 2H14
The company expects to achieve double digit EPS growth this year despite reporting an unfavorable Exchange impact of 3% on sales in Q1. The company said it is "right on track" with the sales progression it expected in January with sales growth before exchange essentially the same as its planned forecast. Abbott expects continued momentum in Established Pharmaceuticals, particularly in Brazil and India. It sees continued in improvement in growth rate with emerging markets becoming a larger component of the business. Expects double sales growth and operating margin for Nutrition in 2H14. Comments taken from Q1 earnings conference call.
News For ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
12:35 EDTABTMylan completes acquisition of assets from Abbott
Mylan N.V. and Mylan (MYL) announced the successful completion of the acquisition of Abbott Laboratories' (ABT) non-U.S. developed markets specialty and branded generics business. Under the previously announced terms of the transaction agreement, Abbott received 110M shares of Mylan N.V., resulting in former Mylan shareholders now owning approximately 78% of Mylan N.V. and Abbott now owning approximately 22% of Mylan N.V. Mylan Inc. and Abbott's non-U.S. developed markets specialty and branded generics business have been reorganized under Mylan N.V., a new public company organized in the Netherlands. Mylan N.V. will be led by the former Mylan Inc. executive team. The company will trade on Nasdaq under the ticker symbol MYL.
February 20, 2015
07:08 EDTABTAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use